

Ermium Therapeutics strengthen its leadership team with the recent appointment of Dr H  l  ne Asnagli as head of biology / pharmacology

Paris, France, November 18th, 2022 – Ermium Therapeutics SAS, a discovery-stage biotechnology company developing innovative therapies for auto-immune diseases, is announcing today the expansion of the Company management team with the appointment of Dr H  l  ne Asnagli as Head of Biology/Pharmacology. Dr Asnagli brings strong expertise in non-clinical R&D for auto-immune diseases.

“We are warmly welcoming H  l  ne as Head of Biology/Pharmacology. Her longstanding non-clinical R&D experience and in-depth knowledge of the field auto-immune diseases are definitely an asset to Ermium Therapeutics” commented, Dr Annegret Van der Aa, CSO/CDO of Ermium Therapeutics.

“We are very pleased to welcome H  l  ne to Ermium Therapeutics in her new role of Head of Biology”, added Jo  l Crouzet, CEO of Ermium Therapeutics. *“We look forward to working with H  l  ne to further develop and execute Ermium Therapeutics’ strategy and move forwards our innovative approach for the treatment of auto-immune diseases”.*

“I am excited to join Ermium Therapeutics management” stated Dr H  l  ne Asnagli; she added *“I am thrilled to bring my expertise and my commitment to Ermium’s very promising immunomodulating therapeutic approach for systemic lupus erythematosus and other type I interferon driven diseases.”*

H  l  ne has more than 20 years of experience in non-clinical R&D, mainly in auto-immune diseases, in various environments ranging from small to well recognized large biotechs in Europe and the US (Step Pharma, TxCell (now part of Sangamo Therapeutics), Serono, Anosys, Celmed BioSciences). H  l  ne has worked on a broad spectrum of programs including cell-based therapies, monoclonal antibodies, and small molecules.

H  l  ne is an immunologist by training with a PhD obtained the Center of immunology CNRS-Inserm in Marseille which she conducted a post-doctoral fellowship at Washington University, St Louis, USA.

About Ermium Therapeutics

Ermium Therapeutics, a discovery stage company dedicated to R&D in the auto-immune disease space, was founded in June 2019. Ermium immunomodulators are orally available compounds aimed to be developed for auto-immune disease indications, particularly interferonopathies, including systemic lupus erythematosus. Such immunomodulators exhibit potent anti-inflammatory properties by efficiently downmodulating the release of type I interferons, and also other key proinflammatory cytokines. The company has obtained *in vivo* POC in different auto-immune / inflammatory disease models. Ermium Therapeutics is based at the Paris Biotech Sant   Incubator – Accelerator located at the Cochin Hospital in Paris. The company has raised  12.3 M from Kurma Partners, Fountain Healthcare Partners, Domain Therapeutics, Eurazeo, and Erganeo, while receiving grants and soft loans from Bpifrance, the French agency for innovation. Ermium Therapeutics has signed a worldwide exclusive license agreement on intellectual property from the CNRS and the Universit   Paris Cit   through an agreement with Erganeo. Ermium Therapeutics

Contact:

Ermium Therapeutics
Dr Jo  l Crouzet
Chief Executive Officer
contact@ermium.com
www.ermium.com